The U.S. Supreme Court has scheduled oral arguments for April 27 to consider Monsanto's appeal, aiming to block thousands of lawsuits alleging its Roundup weedkiller causes cancer. This pivotal hearing could significantly impact Bayer, Monsanto's parent company, which faces substantial financial liabilities. In the specific case, Monsanto Co. v. Durnell, a jury awarded $1.25 million to John Durnell, who claimed non-Hodgkin lymphoma from Roundup exposure. While the WHO classified glyphosate, Roundup's active ingredient, as 'probably carcinogenic to humans,' the EPA has rejected this conclusion. The Supreme Court's decision will be crucial for Bayer's future legal and financial landscape, introducing considerable uncertainty for the company's stock.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis